EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sarcopenia and Frailty in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Impact of Steroid Hormones

Triada Bali, Jennifer Lai, Niki G Mourelatou, Aristi Saridaki iD, Sofia Tsitsou iD, Magdalini Adamantou iD, Aikaterini Kamiliou iD, Christos Chologitas, Margarita Sarri, Dimitra Pavlopoulou, Evangelos Liberopoulos iD, Anna Angelousi iD und 1 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27167431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Triada Bali und 12 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Agiou Th…. Hauptthemen laut MEDLINE: Sarcopenia, Frailty, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to sarcopenia and frailty, but data on white populations remain limited. This study evaluated sarcopenia, physical performance and steroid hormone associations with frailty in European MASLD patients. A cross-sectional study included 245 white MASLD patients. Clinical, biochemical, hormonal and elastography data were collected. Sarcopenia was assessed using dual-energy X-ray absorptiometry alongside mid-arm muscle circumference (MAMC), while physical performance was assessed using the liver frailty index (LFI) and the short physical performance battery (SPPB). Mean age was 56.2 years, 45.7% were male, and median liver stiffness was 5.2 kPa; 76.3% and 33.9% of patients had low MAMC and Appendicular Lean Mass Index, while 13.5% had abnormal SPPB and 16% were frail (i.e., LFI > 4.4). Poor physical performance was linked to lower dehydroepiandrosterone sulfate (DHEAS) levels using both LFI (OR: 0.98, 95% C.I.: 0.96–0.99, p = 0.01) and SPPB (OR: 1.14, 95% C.I.: 1.003–1.22, p = 0.026). Frailty assessed by LFI was associated with increased liver stiffness (OR: 1.24, 95% C.I.: 1.047–1.482, p = 0.013). We concurrently evaluated muscle mass and frailty for the first time in a white MASLD cohort. Lower DHEAS levels were associated with impaired physical performance. Further studies are needed to confirm these findings and their possible therapeutic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaFrailtyNon-alcoholic Fatty Liver DiseaseFatty LiverHumansMaleFemaleMiddle AgedCross-Sectional StudiesAgedAbsorptiometry, PhotonDehydroepiandrosterone Sulfate

Stichwörter der Autor:innen

dehydroepiandrosterone sulfate (DHEAS)dual-energy X-ray absorptiometry (DEXA)liver frailty index (LFI)metabolic dysfunction- associated steatotic liver disease (MASLD)physical performancesarcopeniashort physical performance battery (SPPB)

Substanzen

Dehydroepiandrosterone Sulfate

Autor:innen und Institutionen

  • First Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Agiou Thoma 17, 11526 Athens, Greece.
  • Department of Medicine, Division of Gastroenterology and Hepatology, University of California-San Francisco, 400 Parnassus Avenue, Floor 7, San Francisco, CA 94143, USA.
  • First Department of Propaedeutic and Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Agiou Thoma 17, 11526 Athens, Greece.

ORCID-Profile: Aristi Saridaki, Sofia Tsitsou, Magdalini Adamantou, Aikaterini Kamiliou, Evangelos Liberopoulos, Anna Angelousi, Evangelos Cholongitas

Zitieren

APA

Bali, T., Lai, J., Mourelatou, N. G., Saridaki, A., Tsitsou, S., Adamantou, M., Kamiliou, A., Chologitas, C., Sarri, M., Pavlopoulou, D., Liberopoulos, E., Angelousi, A., & Cholongitas, E. (2026). Sarcopenia and Frailty in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Impact of Steroid Hormones. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27167431

Vancouver

Bali T, Lai J, Mourelatou NG, Saridaki A, Tsitsou S, Adamantou M, et al. Sarcopenia and Frailty in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Impact of Steroid Hormones. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27167431

BibTeX
@article{Bali2026,
  author = {Bali, Triada and Lai, Jennifer and Mourelatou, Niki G and Saridaki, Aristi and Tsitsou, Sofia and Adamantou, Magdalini and Kamiliou, Aikaterini and Chologitas, Christos and Sarri, Margarita and Pavlopoulou, Dimitra and Liberopoulos, Evangelos and Angelousi, Anna and Cholongitas, Evangelos},
  title = {Sarcopenia and Frailty in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Impact of Steroid Hormones},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27167431}
}
Kostenlos starten →